Cholelithiasis and choledocholithiasis after sequential cytarabine and asparaginase.
We report 2 children with acute leukemia who developed symptomatic cholelithiasis and choledocholithiasis shortly after receiving sequential high-dose cytarabine and asparaginase. Known risk factors for gallstone formation were not present in our patients. These children did not experience any unusual therapy-related hepatic toxicity after laparoscopic cholecystectomy.
Sandoval
Claudio
C
Department of Pediatrics, New York Medical College, Valhalla, New York 10595, USA. claudio_sandoval@nymc.edu
Katz
Brian
B
Stringel
Gustavo
G
Jayabose
Somasundaram
S
Lebovics
Edward
E
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001215:Asparaginase / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002769:Cholelithiasis / Q000139:chemically induced*; D003561:Cytarabine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D003561:Cytarabine; D001215:Asparaginase